Morgan Stanley Cuts Insmed (INSM) Price Target to $213

On October 21, 2026, Morgan Stanley maintained its Overweight rating on Insmed Incorporated (NASDAQ:INSM), adjusting its price target down from $218.00 to $213.00. The research note reflects the firm's ongoing view on the biotechnology developer even as the shares trade at a steep discount to Wall Street expectations.

INSM Insmed Incorporated

$93.96 ▼ -46.95% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Morgan Stanley's Call on Insmed

In its October 21, 2026 update, Morgan Stanley kept an Overweight rating on Insmed while trimming its target by $5.00 to $213.00. The adjustment follows a series of moves by other Wall Street firms over the prior weeks. For instance, Roth Capital reiterated a Buy rating and set a $198.00 target on September 15, 2026, while Barclays maintained an Overweight rating with a $207.00 target on September 30, 2026. Wolfe Research downgraded the stock to Peer Perform on October 12, 2026, and HC Wainwright & Co. reiterated a Buy rating with a $220.00 target on the same day.

Other Institutional Activity in Insmed

Institutional investors adjusted sizeable stakes in Insmed ahead of recent quarters. Baker Bros. Advisors, LP grew its holdings by 1,375,111 shares, ending with 8,796,111 shares worth about $826,541,503. Capital International Investors boosted its position by 2,643,093 shares to hold 8,238,124 shares valued at roughly $774,109,307. Darwin Global Management, Ltd. cut its stake significantly, shedding 10,373,548 shares for a 61.7% decrease, leaving it with 6,431,163 shares worth about $604,315,149. Ameriprise Financial, Inc. added 3,121,891 shares, a 102.1% increase to 6,179,571 shares valued at $580,673,880. Orbis Allan Gray Ltd increased its holdings by 4,203,687 shares, a 224.5% jump to 6,076,487 shares worth approximately $570,987,416.

Insmed Incorporated Stock Up 1.0%

Insmed shares recently traded around $94.97 as of October 22, 2026, up about 1.0% from the closing price of $94.04 on the day of Morgan Stanley's note. The stock sits well below its 50-day moving average of $116.60 and its 200-day moving average of $127.89. Recent prices rest near the bottom of its 52-week range, which spans from a low of $90.39 to a high of $212.75.

Recent Earnings

Insmed reported $1,137,634,944 in trailing-twelve-month revenue alongside a trailing-twelve-month EPS of -$4.10. The company recorded a year-over-year revenue growth rate of 296.1%, alongside a net profit margin of -76.9% and a return on equity of -87.2%. The company's next earnings report is scheduled for October 29, 2026.

Dividend

Insmed pays no dividend, registering a dividend yield and payout ratio of 0.0%.

Insider Buying and Selling at Insmed Incorporated

Company insiders completed several transactions in the months leading up to the analyst note. On August 6, 2026, officer Martina Flammer disposed of 27,173 shares valued at $3,494,838. Chief Operating Officer Roger Adsett sold 239,850 shares on August 10, 2026, at an average price of $133.27, totaling $31,964,810. Director Melvin A Sharoky sold 5,000 shares on August 17, 2026, at $127.53 per share for a total of $637,650. Later, on September 9, 2026, director David R Brennan sold 25,000 shares at $124.00 apiece, raising $3,100,000.

Analysts Set New Price Targets

Wall Street analysts maintain a consensus strong buy rating on the stock across 22 analyst opinions, with a mean price target of $196.14. Targets range from a low of $165.00 to a high of $243.00, placing Morgan Stanley's new target near the upper half of the analyst spectrum.

About Insmed Incorporated

Based in Bridgewater, New Jersey, Insmed Incorporated develops therapies for serious and rare diseases. Its commercial portfolio features ARIKAYCE, a treatment for refractory nontuberculous mycobacterial lung infections, alongside ongoing clinical programs targeting other severe respiratory conditions.

Bottom Line

Morgan Stanley's lowered target to $213.00 still leaves a wide gap above the stock's recent price near $94.97. Investors will look to the company's upcoming earnings release on October 29, 2026, for further financial updates.